Non-Arteritic Anterior Ischemic Optic Neuropathy

About The Study:

Sponsored by Quark Pharmaceuticals, the purpose of this study, called QRK, is to test whether an investigational drug called QPI-1007 helps prevent loss of visual acuity, in participants with Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). This study will assess the safety and tolerability of QPI-1007

All participants will be randomized to one of five study groups:

- **Group A**—One 1.5 mg of QPI-1007 administered by intravitreal injection followed by 2 sham injections
- **Group B**—One 3 mg of QPI-1007 administered by intravitreal injection followed by 2 sham injections
- **Group C**—1.5 mg of QPI-1007 administered by intravitreal injection every 2 months, 3 injections total
- **Group D**—3 mg of QPI-1007 administered by intravitreal injection every 2 months, 3 injections total
- **Group E**—3 Sham injections

Participants participating in this study will make up to 8 scheduled study visits over a period of 12 months. Each visit will last anywhere from 2-5 hours.

Key Inclusion Criteria:

- NAION in the study eye, with symptom onset within 14 days
- Age 50-80 years

Key Exclusion Criteria:

- Present use or history or any treatment for the current episode of NAION
- Prior episode of NAION in the study eye only
- Bilateral (simultaneous) NAION
- Macular disease, proliferative diabetic retinopathy or other eye disease limiting visual acuity in study eye only
- Pain on eye movement in either eye
- Glaucoma or OHT in the study eye

For Additional Information Or To Refer A Patient, Contact:

Principal Investigator: Steven Newman, MD
Study Coordinators: Ashton Leone, MPH, CCRP at (434) 243-5737 or aml7q@virginia.edu
Tamika Mercer, COA at (434) 243-2852 or tmm2v@virginia.edu
Allison Weiderhold at (434) 243-2921 or alw5rm@virginia.edu